106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2022 All rights reserved
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to suggest
any particular course of medical treatment. Use of the practice guidelines and this resource are
voluntary. e practice guidelines and additional information are available at www.asco.org/breast-
cancer-guidelines. Copyright © 2022 by American Society of Clinical Oncolog y. All rights reserved.
ASCOMOY7224b
Source
Moy B, Rumble R, Come S et al. Chemotherapy and Targeted erapy for Patients With
Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer at is
Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid
Recommendation Update. J Clin Oncol. 2022 August 4. doi: 10.1200/JCO.22.01533
Moy B, Rumble R, Come S et al. Chemotherapy and Targeted erapy for Patients With
Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer at is Either
Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update. J Clin Oncol.
2021;39(35):3938-3958. doi:10.1200/jco.21.01374.
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical tools
and resources, is available at www.asco.org/breast-cancer-guidelines.
Abbreviations
BRCA, BReast CAncer gene; HER2, human epidermal growth factor receptor2;
HR, hormone receptor; OS, overall survival; PARP, poly-ribose polymerase
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-based B Benefits
outweigh harms
H High Strong
CB/
FC
Consensus-
based/Formal
Consensus
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
N No
recommendation
U Benefits/harms
ratio uncertain
Ins Insufficient
